MA42523A - Anticorps anti-psma, molécules liant l'antigène bispécifiques qui se lient à psma et à cd3 et leurs utilisations - Google Patents

Anticorps anti-psma, molécules liant l'antigène bispécifiques qui se lient à psma et à cd3 et leurs utilisations

Info

Publication number
MA42523A
MA42523A MA042523A MA42523A MA42523A MA 42523 A MA42523 A MA 42523A MA 042523 A MA042523 A MA 042523A MA 42523 A MA42523 A MA 42523A MA 42523 A MA42523 A MA 42523A
Authority
MA
Morocco
Prior art keywords
psma
bind
antigen binding
binding molecules
bispecific antigen
Prior art date
Application number
MA042523A
Other languages
English (en)
Other versions
MA42523B1 (fr
Inventor
Alison Crawford
Drew Dudgeon
Lauric Haber
Jessica R Kirshner
Ashique Rafique
Eric Smith
Gavin Thurston
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority claimed from PCT/US2016/044732 external-priority patent/WO2017023761A1/fr
Publication of MA42523A publication Critical patent/MA42523A/fr
Publication of MA42523B1 publication Critical patent/MA42523B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA42523A 2015-07-31 2016-07-29 Anticorps anti-psma, molécules liant l'antigène bispécifiques qui se lient à psma et à cd3 et leurs utilisations MA42523B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562199823P 2015-07-31 2015-07-31
PCT/US2016/044732 WO2017023761A1 (fr) 2015-07-31 2016-07-29 Anticorps anti-psma, molécules liant l'antigène bispécifiques qui se lient à psma et à cd3 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA42523A true MA42523A (fr) 2018-06-06
MA42523B1 MA42523B1 (fr) 2023-03-31

Family

ID=85793864

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42523A MA42523B1 (fr) 2015-07-31 2016-07-29 Anticorps anti-psma, molécules liant l'antigène bispécifiques qui se lient à psma et à cd3 et leurs utilisations

Country Status (1)

Country Link
MA (1) MA42523B1 (fr)

Also Published As

Publication number Publication date
MA42523B1 (fr) 2023-03-31

Similar Documents

Publication Publication Date Title
MA45712A (fr) Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations
MA53750A (fr) Anticorps anti-bcma, molécules de liaison d'antigène bispécifiques qui se lient au bcma et cd3 et leurs utilisations
MA43164A (fr) Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations
MA46417A (fr) Anticorps anti-steap2, conjugués anticorps-médicament, et molécules bispécifiques de liaison à l'antigène qui se lient à steap2 et cd3, et leurs utilisations
DK3328888T3 (da) ANTI-PSMA-antistoffer, bispecifikke antigenbindingsmolekyler, der binder PSMA AND og CD3, samt anvendelser deraf
MA49457A (fr) Molécules d'anticorps se liant à cd73 et leurs utilisations
ECSP17081420A (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
MA52970A (fr) Anticorps anti-psma x anti-cd28 bispécifiques et leurs utilisations
MA54514A (fr) Anticorps se liant à cd3
DK3328892T3 (da) Bispecifikke antistofkonstruktioner, der binder egfrviii og cd3
MA52771A (fr) Anticorps anti-cd33, anticorps bispécifiques anti-cd33/anti-cd3 et leurs utilisations
MA42935A (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
MA43186A (fr) Anticorps se liant spécifiquement à pd-1 et leurs utilisations
DK3328889T3 (da) Bispecifikke antistofkonstruktioner, der binder dll3 og cd3
UY37083A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso
MA42808A (fr) Anticorps de liaison à l'il-8 et leurs utilisations
MA49565A (fr) Anticorps agonistes qui lient cd137 humain et leurs utilisations
MA49846A (fr) Anticorps qui se lient à l'egfr et à cmet
MA42059A (fr) Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci
MA44072A (fr) Anticorps se liant spécifiquement à hla-dr et leurs utilisations
MA41480A (fr) Anticorps qui se lient au ccr6 et leurs utilisations
MA42440A (fr) Anticorps qui se lient à la sortiline et inhibent la liaison de la progranuline
MA42523A (fr) Anticorps anti-psma, molécules liant l'antigène bispécifiques qui se lient à psma et à cd3 et leurs utilisations
MA39405B1 (fr) Anticorps bispécifiques se liant à cd38 et cd3